PHARMACYTE BIOTECH, INC. Dividends, Preferred Stock
PHARMACYTE BIOTECH, INC. (PMCB) reported Dividends, Preferred Stock of $83.40 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Shareholders' Equity › Dividends, Preferred Stock
us-gaap:DividendsPreferredStock · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for the quarter ending 2026-07-31 was $83.40K.
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for the quarter ending 2026-04-30 was $83.40K.
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for the quarter ending 2026-01-31 was $98.46K.
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for the quarter ending 2025-10-31 was $96.64K, a 78.23% decline year-over-year.
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for fiscal 2026 was $278.50K, a 75.35% decline from fiscal 2025.
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for fiscal 2025 was $1.13M, a 55.13% decline from fiscal 2024.
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for fiscal 2024 was $2.52M.
- PHARMACYTE BIOTECH, INC. dividends, preferred stock for fiscal 2023 was $0.00.
| Period end | Dividends, Preferred Stock 3 month | Dividends, Preferred Stock 6 month | Dividends, Preferred Stock 9 month | Dividends, Preferred Stock 12 month |
|---|---|---|---|---|
| 2026-07-31 | $83.40K 10-Q · filed 2026-09-14 | $166.80K derived: sum of 2 quarters · filed 2026-09-14 | $265.26K derived: sum of 3 quarters · filed 2026-09-14 | $361.89K derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $83.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $181.86K derived: sum of 2 quarters · filed 2026-07-29 | $278.50K derived: sum of 3 quarters · filed 2026-07-29 | $278.50K 10-K · filed 2026-07-29 |
| 2026-01-31 | $98.46K 10-Q · filed 2026-03-17 | $195.10K derived: sum of 2 quarters · filed 2026-03-17 | $195.10K 10-Q · filed 2026-03-17 | $195.10K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $96.64K 10-Q · filed 2025-12-18 | $96.64K 10-Q · filed 2025-12-18 | $96.64K derived: sum of 3 quarters · filed 2026-09-14 | $96.64K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $0.00 10-Q · filed 2026-09-14 | $0.00 derived: sum of 2 quarters · filed 2026-09-14 | $0.00 derived: sum of 3 quarters · filed 2026-09-14 | $443.96K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $0.00 derived: sum of 2 quarters · filed 2026-07-29 | $443.96K derived: sum of 3 quarters · filed 2026-07-29 | $1.13M 10-K · filed 2026-07-29 |
| 2025-01-31 | $0.00 10-Q · filed 2026-03-17 | $443.96K derived: sum of 2 quarters · filed 2026-03-17 | $1.13M 10-Q · filed 2026-03-17 | $1.96M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-10-31 | $443.96K 10-Q · filed 2025-12-18 | $1.13M 10-Q · filed 2025-12-18 | $1.96M derived: sum of 3 quarters · filed 2025-12-18 | $2.74M derived: sum of 4 quarters · filed 2025-12-18 |
| 2024-07-31 | $685.80K 10-Q · filed 2025-09-15 | $1.52M derived: sum of 2 quarters · filed 2025-09-15 | $2.30M derived: sum of 3 quarters · filed 2025-09-15 | $2.88M derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | $829.40K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | $1.61M derived: sum of 2 quarters · filed 2025-08-11 | $2.20M derived: sum of 3 quarters · filed 2025-08-11 | $2.52M 10-K · filed 2025-08-11 |
| 2024-01-31 | $781.51K 10-Q · filed 2025-03-17 | $1.37M derived: sum of 2 quarters · filed 2025-03-17 | $1.69M 10-Q · filed 2025-03-17 | $1.69M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | $586.89K 10-Q · filed 2024-12-13 | $906.74K 10-Q · filed 2024-12-13 | $906.74K derived: sum of 3 quarters · filed 2024-12-13 | $906.74K derived: sum of 4 quarters · filed 2024-12-13 |
| 2023-07-31 | $319.85K 10-Q · filed 2024-09-17 | $319.85K derived: sum of 2 quarters · filed 2024-09-17 | $319.85K derived: sum of 3 quarters · filed 2024-09-17 | $319.85K derived: sum of 4 quarters · filed 2024-09-17 |
| 2023-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-13 | $0.00 derived: sum of 2 quarters · filed 2024-08-13 | $0.00 derived: sum of 3 quarters · filed 2024-08-13 | $0.00 10-K · filed 2024-08-13 |
| 2023-01-31 | $0.00 10-Q · filed 2024-03-18 | $0.00 derived: sum of 2 quarters · filed 2024-03-18 | $0.00 10-Q · filed 2024-03-18 | |
| 2022-10-31 | $0.00 10-Q · filed 2023-12-15 | $0.00 10-Q · filed 2023-12-15 | ||
| 2022-07-31 | $0.00 10-Q · filed 2023-09-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |